Long acting GLP-1 receptor agonist (injectable)
Bofanglutide 24 mg injection every 2 weeks
BOFANG_SC_24MG_Q2W
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -10.90 (-17.87 to -1.86) | 0.69 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -11.78 (-17.21 to -3.62) | 0.78 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.53 (-6.11 to 8.70) | 0.57 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.95 (0.06 to 8.67) | 0.55 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.59 (2.46 to 13.70) | 0.29 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.19 (1.79 to 9.84) | 0.51 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.57 (1.12 to 5.92) | 0.37 |